Celgene eyes earlier US filing for apremilast in psoriatic arthritis after positive data
This article was originally published in Scrip
Executive Summary
Celgene has shortened the timeframe in which it plans to submit a new drug application (NDA) to the US FDA for apremilast in the treatment of psoriatic arthritis (PsA) based on positive topline results from the last two of three Phase III clinical trials for its novel, oral small molecule inhibitor of phosphodiesterase 4 (PDE4).